Dr. Virginia Kaklamani, MD
What this data tells you about Dr. Kaklamani
Dr. Virginia Kaklamani is a medical oncology in San Antonio, TX, with 19 years in practice. Based on federal Medicare data, Dr. Kaklamani performed 12,024 Medicare services across 770 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kaklamani received a total of $780,487 from 28 pharmaceutical and/or device companies across 561 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kaklamani is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 3,400 | $43 | $157 |
| Anti-nausea injection (fosaprepitant) | 2,400 | $0 | $1 |
| BCG treatment for bladder cancer | 1,952 | $2 | $9 |
| Denosumab injection (Prolia/Xgeva) | 1,560 | $18 | $63 |
| Anti-nausea injection (ondansetron/Zofran) | 708 | $0 | $0 |
| Dexamethasone injection (steroid) | 668 | $0 | $0 |
| Office visit, established patient (30-39 min) | 340 | $90 | $313 |
| Anti-nausea injection (Aloxi/palonosetron) | 160 | $1 | $6 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 131 | $3 | $11 |
| Administration of chemotherapy into vein, 1 hour or less | 106 | $97 | $381 |
| Injection of additional new drug or substance into vein | 98 | $12 | $47 |
| Office visit, established patient, complex (40-54 min) | 82 | $133 | $439 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 74 | $22 | $87 |
| Instillation of anti-cancer drug into bladder | 58 | $68 | $257 |
| Injection, magnesium sulfate, per 500 mg | 52 | $1 | $2 |
| New patient office visit, complex (60-74 min) | 36 | $151 | $537 |
| Administration of chemotherapy into vein, each additional hour | 31 | $22 | $86 |
| Drug injection, under skin or into muscle | 29 | $11 | $41 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $48 | $188 |
| Infusion into a vein for hydration, each additional hour | 26 | $10 | $39 |
| Infusion, normal saline solution , 1000 cc | 26 | $2 | $8 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $55 | $225 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 21 | $47 | $195 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $26 | $96 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (73%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for medical oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kaklamani is a mixed practice specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 2%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kaklamani experienced with pembrolizumab injection (keytruda)?
Does Dr. Kaklamani receive payments from pharmaceutical companies?
How do Dr. Kaklamani's costs compare to other medical oncologys in San Antonio?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology